The 35th CINP World Congress of Neuropsychopharmacology

Presentation information

[CINP2024] Poster Session

CINP2024 » Poster Session

Schizophrenia 5 - Clinical (3)

Sun. May 26, 2024 1:30 PM - 2:30 PM CINP Poster Session Hall (Lobby Gallery)

[P500] Evenamide as add-on treatment for patients with chronic schizophrenia not responding adequately to their current antipsychotic medication: results of a potentially pivotal, phase II/III, international, randomized, double blind, placebo-controlled trial

*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Rodolfo Giuliani2, Richard Hartman3 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

Keywords:Schizophrenia, Phase 2/3 trial, glutamate modulation, add-on treatment, evenamide

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Password